PDSB Fundamental Analysis - PDS BIOTECHNOLOGY CORP

Fundamental Rating

Overall PDSB gets a fundamental rating of 1 out of 10. We evaluated PDSB against 558 industry peers in the Biotechnology industry. Both the profitability and financial health of PDSB have multiple concerns. PDSB is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

PDSB had negative earnings in the past year.

In the past year PDSB has reported a negative cash flow from operations.

PDSB had negative earnings in each of the past 5 years.

PDSB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -75.48%, PDSB is doing worse than 67.38% of the companies in the same industry.

PDSB has a worse Return On Equity (-158.73%) than 63.80% of its industry peers.

		Industry Rank	Sector Rank
ROA	-75.48%
ROE	-158.73%
ROIC	N/A

ROA(3y)-69.42%

ROA(5y)-56.3%

ROE(3y)-151.69%

ROE(5y)-107.33%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PDSB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PDSB has more shares outstanding than it did 1 year ago.

PDSB has more shares outstanding than it did 5 years ago.

PDSB has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -5.76, we must say that PDSB is in the distress zone and has some risk of bankruptcy.

PDSB has a worse Altman-Z score (-5.76) than 62.54% of its industry peers.

A Debt/Equity ratio of 0.29 indicates that PDSB is not too dependend on debt financing.

PDSB's Debt to Equity ratio of 0.29 is on the low side compared to the rest of the industry. PDSB is outperformed by 72.04% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.29
Debt/FCF	N/A
Altman-Z	-5.76

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

PDSB has a Current Ratio of 2.33. This indicates that PDSB is financially healthy and has no problem in meeting its short term obligations.

With a Current ratio value of 2.33, PDSB is not doing good in the industry: 71.68% of the companies in the same industry are doing better.

A Quick Ratio of 2.33 indicates that PDSB has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 2.33, PDSB is doing worse than 69.71% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.33
Quick Ratio	2.33

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PDSB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.39%, which is quite impressive.

EPS 1Y (TTM)31.39%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%30%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PDSB will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.79% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y17.81%

EPS Next 2Y3.88%

EPS Next 3Y3.29%

EPS Next 5Y17.79%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PDSB. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PDSB. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y3.88%

EPS Next 3Y3.29%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PDSB!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PDS BIOTECHNOLOGY CORP

NASDAQ:PDSB (6/24/2025, 8:00:00 PM)

Premarket: 1.65 +0.05 (+3.12%)

1.6

+0.06 (+3.9%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-14 2025-05-14/bmo

Earnings (Next)08-11 2025-08-11

Inst Owners18.11%

Inst Owner Change93.65%

Ins Owners2.11%

Ins Owner Change1.81%

Market Cap73.14M

Analysts82.22

Price Target7.65 (378.13%)

Short Float %6.55%

Short Ratio5.61

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)21.06%

Min EPS beat(2)16.54%

Max EPS beat(2)25.59%

EPS beat(4)3

Avg EPS beat(4)18.31%

Min EPS beat(4)-2.15%

Max EPS beat(4)33.29%

EPS beat(8)6

Avg EPS beat(8)16.67%

EPS beat(12)8

Avg EPS beat(12)3.48%

EPS beat(16)10

Avg EPS beat(16)5.05%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-1.64%

PT rev (3m)-25.93%

EPS NQ rev (1m)0%

EPS NQ rev (3m)33.17%

EPS NY rev (1m)9.45%

EPS NY rev (3m)36.28%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	3.27
P/tB	3.27
EV/EBITDA	N/A

EPS(TTM)-0.94

EYN/A

EPS(NY)-0.95

Fwd EYN/A

FCF(TTM)-0.75

FCFYN/A

OCF(TTM)-0.75

OCFYN/A

SpS0

BVpS0.49

TBVpS0.49

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-75.48%
ROE	-158.73%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-69.42%

ROA(5y)-56.3%

ROE(3y)-151.69%

ROE(5y)-107.33%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.29
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.33
Quick Ratio	2.33
Altman-Z	-5.76

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)31.39%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%30%

EPS Next Y17.81%

EPS Next 2Y3.88%

EPS Next 3Y3.29%

EPS Next 5Y17.79%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y19.2%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-10.33%

EBIT Next 3Y-15.94%

EBIT Next 5Y-15%

FCF growth 1Y-4.99%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-4.9%

OCF growth 3YN/A

OCF growth 5YN/A

PDS BIOTECHNOLOGY CORP (PDSB) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens